MicroRNA fingerprints during human megakaryocytopoiesis
View Patent ↗The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of cancer and myeloproliferative disorders. The invention also provides methods of identifying anti-cancer agents.
1. A method of diagnosing acute megakaryoblastic leukemia in a subject, comprising:
i) comparing the level of at least one miR gene product in a subject sample to control, wherein the at least one miR gene product is selected from the group consisting of: miR-101; miR-126; miR-99a; miR-99-prec; miR-106; miR-339; miR-99b; miR-149; miR-33; miR-135; and miR-20; and
ii) diagnosing acute megakaryoblastic leukemia in the event that the at least one miR gene product level is higher in the sample compared to control.
2. The method of claim 1 , wherein the control is the level of the at least one miR gene product from a subject that does not have a acute megakaryoblastic leukemia disorder.
3. The method of claim 1 , wherein the subject is a human.
4. The method of claim 1 , wherein the control is the level of the at least one miR gene product from a reference sample comprising non-differentiating megakaryocyte progeny and/or megakaryocytes.
5. A method of diagnosing acute megakaryoblastic leukemia in a subject, comprising:
i) comparing the levels of at least two miR gene products in a subject sample to control, wherein the at least two miR gene products are selected from the group consisting of: miR-101; miR-126; miR-99a; miR-99-prec; miR-106; miR-339; miR-99b; miR-149; miR-33; miR-135; and miR-20, and
ii) diagnosing or acute megakaryoblastic leukemia in the event that the at least two miR gene product levels are higher in the sample compared to control.